Few biotechnology firms without a late-stage or marketed product have gone public through the current 2003-2004 financing window. In fact, among the 28 biotech IPOs in the US during this time frame tracked in Windhover's Strategic Intelligence Systems, only two firms—Alnylam Pharmaceuticals Inc. (an Alnylam Holding Co. subsidiary) and Momenta Pharmaceuticals Inc. —braved the IPO waters without a clinical-stage project [See Deal]. Just two more, Anadys Pharmaceuticals Inc. and Memory Pharmaceuticals Corp. , were as far along as Phase I [See Deal]. [Note: we've excluded Momenta from this analysis: although it had no candidates in the clinic when it went public, it would be disingenuous to view the company as a preclinical-stage biotech. Its sugar sequencing technology will initially yield non-NME drug candidates more suitable to ANDAs—like its generic version of Sanofi-Aventis SA 's enoxaparin sodium (Lovenox).]
The markets' preference for biotech IPO candidates with late-stage products is well-known and is borne out in an analysis of...







